bacteroides fragilis BF839 + dragon protein

bacteroides fragilis BF839 + dragon protein is an experimental combination therapy being developed by The Second Affiliated Hospital of Guangzhou Medical University for the treatment of Parkinson's disease (PD). The therapy consists of a specific non-toxigenic strain of the bacterium *Bacteroides fragilis* (BF839) and a protein component referred to as "dragon protein." BF839 is a live biotherapeutic product that aims to modulate the gut-brain axis; research indicates it can reduce neuroinflammation, lower levels of pro-inflammatory cytokines like TNF-alpha, and inhibit the aggregation of alpha-synuclein in the central nervous system. The "dragon protein" component likely refers to either the Repulsive Guidance Molecule b (RGMb), a BMP co-receptor involved in neuronal survival and axonal guidance that is a key focus of the developer's research, or a commercial protein preparation (such as lumbrokinase) often marketed alongside BF839 in China for its potential to clear protein aggregates and improve microcirculation. This combination approach seeks to provide neuroprotection and}

Other names

Bacteroides fragilis strain BF839Dragon proteinRGMbRepulsive guidance molecule bLumbrokinase